A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes and Stable Coronary Artery Disease

Mediators of Inflammation

Volumn 2017, Issue , 2017, Pages

  Njerve, Ida Unhammer ^a,b   Åkra, Sissel ^a   Weiss, Thomas W ^c   Solheim, Svein ^a   Øvstebø, Reidun ^a   Aass, Hans Christian D ^a   Byrkjeland, Rune ^a,b   Arnesen, Harald ^a,b   Seljeflot, Ingebjørg ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CX3CR1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FRACTALKINE; GLIMEPIRIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SAXAGLIPTIN; TUMOR NECROSIS FACTOR; ADAMANTANE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CRYOPRESERVATION; DIABETIC PATIENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION; ANALOGS AND DERIVATIVES; METABOLISM; MONONUCLEAR CELL;

ADAMANTANE; AGED; ANTI-INFLAMMATORY AGENTS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; METFORMIN; MIDDLE AGED;

EID: 85020027609     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2017/5380638     Document Type: Article

References (27)

1. S. Dhillon, "Saxagliptin: a review in type 2 diabetes," Drugs, vol. 75, no. 15, pp. 1783-1796, 2015.
2. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., "Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the study of diabetes," Diabetologia, vol. 58, no. 3, pp. 429-442, 2015.
3. D. J. Drucker and M. A. Nauck, "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes," Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
4. G. P. Fadini and A. Avogaro, "Cardiovascular effects of DPP-4 inhibition: beyond GLP-1," Vascular Pharmacology, vol. 55, no. 1-3, pp. 10-16, 2011.
5. F. Vittone, A. Liberman, D. Vasic et al., "Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice," Diabetologia, vol. 55, no. 8, pp. 2267-2275, 2012.
6. J. Matsubara, S. Sugiyama, K. Sugamura et al., "A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice," Journal of the American College of Cardiology, vol. 59, no. 3, pp. 265-276, 2012.
7. Z. Shah, T. Kampfrath, J. A. Deiuliis et al., "Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis," Circulation, vol. 124, no. 21, pp. 2338-2349, 2011.
8. J. Matsubara, S. Sugiyama, E. Akiyama et al., "Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes," Circulation Journal, vol. 77, no. 5, pp. 1337-1344, 2013.
9. A. Makdissi, H. Ghanim, M. Vora et al., "Sitagliptin exerts an antinflammatory action," The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 9, pp. 3333-3341, 2012.
10. N. Satoh-Asahara, Y. Sasaki, H. Wada et al., "A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients," Metabolism, vol. 62, no. 3, pp. 347-351, 2013.
11. T. Mita, N. Katakami, H. Yoshii et al., "Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)," Diabetes Care, vol. 39, no. 1, pp. 139-148, 2016.
12. R. Øvstebø, H. C. Aass, K. B. Haug et al., "LPS from Neisseria meningitidis is crucial for inducing monocyte- and microparticle-associated tissue factor activity but not for tissue factor expression," Innate Immunity, vol. 18, no. 4, pp. 580-591, 2012.
13. K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method," Methods, vol. 25, no. 4, pp. 402-408, 2001.
14. A. S. Møller, R. Øvstebø, A. B. Westvik, G. B. Joø, K. B. Haug, and P. Kierulf, "Effects of bacterial cell wall components (PAMPs) on the expression of monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and the chemokine receptor CCR2 by purified human blood monocytes," Journal of Endotoxin Research, vol. 9, no. 6, pp. 349-360, 2003.
15. T. P. Singh, V. N. Vangaveti, and U. H. Malabu, "Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis-a review," Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 9, no. 4, pp. 223-229, 2015.
16. K. N. Couper, D. G. Blount, and E. M. Riley, "IL-10: The master regulator of immunity to infection," Journal of Immunology, vol. 180, no. 9, pp. 5771-5777, 2008.
17. M. R. de Waal, J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries, "Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes," The Journal of Experimental Medicine, vol. 174, no. 5, pp. 1209-1220, 1991.
18. D. Reinhold, S. Ansorge, and E. D. Schleicher, "Elevated glucose levels stimulate transforming growth factor-β1 (TGF-β1), suppress interleukin IL-2, IL-6 and IL-10 production and DNA synthesis in peripheral blood mononuclear cells," Hormone and Metabolic Research, vol. 28, no. 6, pp. 267-270, 1996.
19. I. Torres-Castro, Ú. D. Arroyo-Camarena, C. P. Martínez-Reyes et al., "Human monocytes and macrophages undergo M1-type inflammatory polarization in response to high levels of glucose," Immunology Letters, vol. 176, pp. 81-89, 2016.
20. M. R. Rizzo, M. Barbieri, R. Marfella, and G. Paolisso, "Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition," Diabetes Care, vol. 35, no. 10, pp. 2076-2082, 2012.
21. M. Takemoto and J. K. Liao, "Pleiotropic effects of 3-hydroxy- 3-methylglutaryl coenzyme a reductase inhibitors," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 11, pp. 1712-1719, 2001.
22. K. A. Müller, M. Chatterjee, D. Rath, and T. Geisler, "Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD," Thrombosis and Haemostasis, vol. 114, no. 3, pp. 498-518, 2015.
23. B. M. Scirica, D. L. Bhatt, E. Braunwald et al., "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus," The New England Journal of Medicine, vol. 369, no. 14, pp. 1317-1326, 2013.
24. J. B. Green, M. A. Bethel, P. W. Armstrong et al., "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes," The New England Journal of Medicine, vol. 373, no. 3, pp. 232-242, 2015.
25. W. B. White, C. P. Cannon, S. R. Heller et al., "Alogliptin after acute coronary syndrome in patients with type 2 diabetes," The New England Journal of Medicine, vol. 369, no. 14, pp. 1327-1335, 2013.
26. T. V. Fiorentino and G. Sesti, "Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP- 4) inhibitors," Endocrine, vol. 53, no. 2, pp. 372-380, 2016.
27. B. Zinman, C. Wanner, J. M. Lachin et al., "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes," The New England Journal of Medicine, vol. 373, no. 22, pp. 2117-2128, 2015.